Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT)‘s stock had its “outperform” rating reaffirmed by equities research analysts at BMO Capital Markets in a report released on Friday, September 22nd. They presently have a $160.00 price target on the biopharmaceutical company’s stock, down from their previous price target of $221.00. BMO Capital Markets’ price target would suggest a potential upside of 177.63% from the company’s current price.
A number of other equities analysts also recently issued reports on ICPT. Wedbush reissued an “outperform” rating and set a $253.00 price target on shares of Intercept Pharmaceuticals in a research report on Friday, August 25th. Credit Suisse Group set a $201.00 price objective on Intercept Pharmaceuticals and gave the stock a “buy” rating in a research note on Saturday, June 3rd. ValuEngine cut Intercept Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, September 22nd. Cantor Fitzgerald restated an “underweight” rating and set a $69.00 price objective (up from $60.00) on shares of Intercept Pharmaceuticals in a research note on Monday, July 31st. Finally, BidaskClub cut Intercept Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, August 4th. Three investment analysts have rated the stock with a sell rating, eight have assigned a hold rating, nine have given a buy rating and one has issued a strong buy rating to the company. The stock currently has an average rating of “Hold” and a consensus price target of $162.88.
Shares of Intercept Pharmaceuticals (ICPT) traded up 2.20% during trading on Friday, reaching $58.90. The company’s stock had a trading volume of 2,007,896 shares. The company has a 50-day moving average price of $106.75 and a 200-day moving average price of $115.74. The stock’s market cap is $1.48 billion. Intercept Pharmaceuticals has a one year low of $57.31 and a one year high of $172.75.
Intercept Pharmaceuticals (NASDAQ:ICPT) last posted its quarterly earnings results on Monday, July 31st. The biopharmaceutical company reported ($3.46) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($3.62) by $0.16. Intercept Pharmaceuticals had a negative return on equity of 135.24% and a negative net margin of 543.35%. The business had revenue of $30.89 million for the quarter, compared to the consensus estimate of $27.50 million. During the same quarter in the prior year, the company earned ($3.14) EPS. The business’s revenue was up 459.6% compared to the same quarter last year. On average, equities research analysts forecast that Intercept Pharmaceuticals will post ($13.99) earnings per share for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: This report was first published by The Ledger Gazette and is the property of of The Ledger Gazette. If you are accessing this report on another site, it was illegally copied and reposted in violation of United States & international copyright & trademark legislation. The correct version of this report can be read at https://ledgergazette.com/2017/09/29/intercept-pharmaceuticals-inc-icpt-pt-lowered-to-160-00-at-bmo-capital-markets.html.
In other news, CFO Sandip Kapadia sold 1,431 shares of the stock in a transaction dated Monday, July 3rd. The stock was sold at an average price of $121.59, for a total value of $173,995.29. Following the transaction, the chief financial officer now directly owns 20,569 shares of the company’s stock, valued at $2,500,984.71. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Mark Pruzanski sold 1,434 shares of the stock in a transaction dated Monday, July 3rd. The shares were sold at an average price of $121.78, for a total value of $174,632.52. Following the completion of the transaction, the chief executive officer now directly owns 570,284 shares in the company, valued at $69,449,185.52. The disclosure for this sale can be found here. Insiders sold 8,013 shares of company stock worth $966,747 over the last three months. Corporate insiders own 9.20% of the company’s stock.
A number of institutional investors have recently bought and sold shares of the stock. WFG Advisors LP grew its holdings in Intercept Pharmaceuticals by 16.4% during the second quarter. WFG Advisors LP now owns 888 shares of the biopharmaceutical company’s stock worth $108,000 after acquiring an additional 125 shares during the period. Dynamic Technology Lab Private Ltd grew its holdings in Intercept Pharmaceuticals by 85.6% during the second quarter. Dynamic Technology Lab Private Ltd now owns 6,798 shares of the biopharmaceutical company’s stock worth $824,000 after acquiring an additional 3,136 shares during the period. Public Employees Retirement System of Ohio grew its holdings in Intercept Pharmaceuticals by 15.0% during the second quarter. Public Employees Retirement System of Ohio now owns 7,385 shares of the biopharmaceutical company’s stock worth $894,000 after acquiring an additional 965 shares during the period. Asymmetry Capital Management L.P. acquired a new stake in Intercept Pharmaceuticals during the second quarter worth about $3,580,000. Finally, Nomura Holdings Inc. acquired a new stake in Intercept Pharmaceuticals during the second quarter worth about $366,000. 82.19% of the stock is currently owned by hedge funds and other institutional investors.
Intercept Pharmaceuticals Company Profile
Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.
Receive News & Ratings for Intercept Pharmaceuticals Inc. Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Intercept Pharmaceuticals Inc. and related companies with MarketBeat.com’s FREE daily email newsletter.